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Background: Unhealthy diet, especially consumption of trans fatty acids (TFAs), is a known risk factor for cardio-
vascular disease (CVD), a leading cause of death in Austria. In 2009, Austria introduced a law regulating the
content of TFAs in foods. The aim of this study was to assess the impact of the TFA regulation on CVD-related
outcomes.Methods: The study evaluated the TFA regulation as an intervention in a natural experiment. Two study
periods were assessed: pre-intervention (1995–2009) and post-intervention (2010–14). The study compared the
age-standardized death rates per 100 000 population for CVD outcomes with those of a ‘synthetic’ international
comparator population, created from data of OECD countries where TFA regulation has not been implemented,
but where the population is otherwise comparable. Results: There was a continuous decrease in CVD-related
mortality throughout the study period in both the synthetic international comparator population, as well as in
the adult Austrian population, with no significant change in this trend observed as an effect of TFA regulation.
Conclusions: Whilst the results are counterintuitive, given the established link between TFA consumption and an
increased risk of CVD, there are many possible explanations: high prevalence of tobacco smoking, changes in TFA
content in foods due to international guidance as opposed to formal regulation and a beneficial impact of TFA
regulation on sub-groups of the population that might not be detected with nationally aggregated data.
However, reduction in TFAs should still be considered an important part of risk factor reduction for CVD and
other non-communicable diseases.
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Introduction
A growing number of health problems [such as cardiovasculardiseases (CVD), obesity, hypertension, stroke, type II diabetes
mellitus, chronic kidney disease, cognitive insufficiency, atrial fibril-
lation] are caused or influenced by dietary patterns through adverse
effects on glucose-insulin homeostasis, oxidative stress, inflamma-
tion, endothelial health, hepatic function, adipocyte metabolism,
visceral adiposity etc.1,2 The cardio-metabolic consequences of
different dietary patterns and nutrient intakes have been researched
to varying degrees, using a variety of methods, including interven-
tional trials, prospective cohorts and randomized controlled trials.2
This has led the World Health Organization (WHO) and national
authorities to adopt nutrient- and food-based dietary guidelines,
including the publication of updated WHO guidelines on sodium
intake, free sugars and, most recently, saturated and trans fatty
acid (TFA) fat intake in 2018.3 The promotion of healthy diets is
now a global policy priority for public health, as reflected in
increasing commitments by countries at national and international
levels.
TFAs are unsaturated fatty acids that contain at least one non-
conjugated double bond in the trans configuration and can be found
naturally in ruminant foods (rTFA) or in industrial produced oils
(iTFA). iTFAs were widely used during the 1970s–80s when
margarine was advocated as a butter substitute due to the lower
saturated fat content.4 However since the 1990s it has become
evident that high intake of TFA is associated with many negative
health outcomes.5 Based on multiple reports, it was concluded that
there were no nutritional benefits of TFA and there were clear
adverse effects especially in increasing the risk and mortality of
CVD, therefore limiting their consumption and contents in
various food items should be a policy priority.6 Based on the
available evidence, reviewed according the GRADE methodology,
the WHO has recommended reducing the intake of TFA to <1%
of total energy intake among children and adolescents.3 Denmark
was the first country globally to introduce a trans-fat ban via legis-
lation adopted in 2003, setting limits for industrially produced TFA
in the food supply (<2 g TFA per 100 g total fat).7 Many countries
have since followed the Danish example and adopted policies to
reduce or eliminate of TFAs in food products.8
In Austria, a regulation of TFA in foods was introduced in 2009.9
Prior to this, monitoring of the food supply demonstrated that food
products available on the Austrian market contained very high levels
of TFA. This was particularly pronounced in margarines, conveni-
ence food products and fast foods, which contained on average 7.83,
3.64 and 2.17% TFA/FA, respectively. In fact, before 2008, 42% of
the sampled food products (including various convenience food
products, fast food as well as margarines, oils and cooking and
frying fats) had a TFA content over 2% and more than 10% of
the products had a TFA content over 10% of total energy.10
The food regulation law regarding the content of TFA in food
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For multi-ingredient processed foods with a total fat content below
20%, TFAs were restricted to 4/100g of total fat and for processed
foods with a total fat content below 3% TFA to 10/100 g of total fat.9
We aimed to investigate if these regulations led to a significant
reduction in cardiovascular outcomes such as CVD and mortality
due to coronary heart disease (CHD) in Austria. As CVD (ICD-10
diagnoses I00-I99) and CHD (ICD-10 diagnoses I20-I25) specific
mortality are multimodal and influenced by a variety of individual
risk factors such as age, smoking habits, hypertension, GDP and
healthcare provision,8,11–13 these factors must be taken into consid-
eration during the analysis.
Methods
Data extraction and sources
Data were extracted from the OECD database and are comparable
across OECD members.14 Our study period was between 1995 and
2014. A pool of comparator countries were chosen if they did not
implement a TFA regulation during the study period and if data
points were available for more than 60% of cases in the database.
Our original data set included 13 countries: Australia, Estonia,
Finland, France, Ireland, Israel, Italy, Luxembourg, Mexico, New
Zealand, Portugal, Sweden and UK) with data available from 1995
until 2014. If date for single years in the respective countries were
missing, the values were replaced using linear interpolation.
Intervention and dose
The introduction of the TFA regulation in the year 2009 is a public
health intervention enacted by the Ministry of Health, Families and
Youth (currently Ministry of Labour, Social Affairs, Health and
Consumer Protection) in response to an analysis of the TFA
content of food (in g TFA/100g total fat). These data are provided
in table 1. Our study has two study periods: before (1995–2009) and
after (2010–14) the TFA regulation.
Outcomes
The main outcomes of interest were all-cause mortality, CVD
mortality (mortality due to ICD-10 diagnoses I00-I99) and CHD
mortality rates (mortality due to ICD-10 diagnoses I20-I25) per
100 000 people annually.15 The following potential confounders
were taken into account: age and gender distribution of the
population, GDP per capita, health expenditures per capita as well
as the prevalence of smoking, obesity, hypertension and diabetes
mellitus.
Statistical analysis
This study quantifies the effect of the Austrian TFA regulation
exploiting a natural experiment,18–20 comprising of two elements:
(i) the change of outcomes before and after the introduction of the
regulation; (ii) comparator countries which did not have any such
TFA related policies.16–18 We employed the ‘synthetic control
method’ and identified comparator countries according to data
trends similar to that of Austria before the intervention. If the
difference in pre-intervention trends between Austria and its
‘synthetic control’ are sufficiently small, corresponding post-
treatment differences may be plausibly attributed to the effect of
the regulation.19 The underlying assumption is that unobserved
confounders remain unchanged following the intervention.
Our empirical model compared Austria’s reported all-cause
mortality, CVD mortality and CHD mortality rates over time with
those of the synthetic control group. The synthetic control group
was composed as a weighted average of the OECD countries
included in the analysis.20 The weights assigned to the control
countries were non-negative and equal to the sum of one. A
recursive algorithm selected the weights optimally so that the
synthetic control group most closely resembled the mortality rates
and risk factors in Austria in the pre-treatment period.
Data preparation and all statistical analysis were carried out by
using the software GNU R version 3.4.4.21 The model was calculated
using the synthetic control method, with all statistical routines being
implemented using the R package MSCMT.22–24
The synthetic control method does not lend itself to classical
hypothesis testing given that there is only one treatment unit and
no sampling error due to the use of aggregate data. Instead, inference
is exact and the test assesses whether effect sizes ‘stand’ out from the
data. We conducted a series of placebo tests by iteratively and falsely
applying the TFA regulation in 2009 to each of the 13 synthetic
control countries (shifting Austria to the control pool).
Afterwards, we computed the estimated effect associated with each
placebo run. This iterative procedure gives a distribution of
estimated gaps for the control countries where no TFA regulation
had been introduced. With the results of the placebo tests, pseudo-
P-values were computed by calculating and ranking the ratios of
post- to pre-intervention root mean squared prediction errors for
all Austria and all placebos runs.
Austria did not fully comply with the WHO Framework
Convention on Tobacco Control, especially in the implementation
of ‘Protecting people from tobacco smoke’ (banning smoking in
public places) by introducing exceptions (such as designated
smoking rooms, or allowing for smoking and non-smoking
places). As tobacco is a major risk factor and potential
confounder, we used sensitivity analysis to assess its influence: we
excluded those OECD countries with full implementation of the ban
in public places—Australia, Ireland, New Zealand and UK. The final
list of nine included countries was Estonia, Finland, France, Israel,
Italy, Luxembourg, Mexico, Portugal and Sweden.25
All calculations were done separately for women, men and both
sexes together.
Results
In table 1, the TFA contents of food samples in Austria are shown.
There was a remarkable and significant decrease of TFA contents in
total, as well as in vegetable fats, margarines, vegetable oils and fine
Table 1 Trans fatty acid (TFA) content in food samples (g TFA/g fat) 2007–09 (before) vs. 2010–17 (after) introducing TFA regulation in
Austria
Before TFA regulation After TFA regulation
Number of samples Mean Median Number of samples Mean Median P-value
All 535 3.21 0.60 2912 0.70 0.29 <0.01
WG-0501 132 8.22 1.00 250 1.31 0.48 <0.01
Vegetable fats, margarine
WG-0502 12 5.29 0.90 1163 0.22 0.11 <0.01
Vegetable oils
WG-0702 218 1.89 0.49 501 1.13 0.40 0.01
Fine bakery products—baked by confectioner
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bakery products following the introduction of TFA regulation in
Austria.
A comparison of Austrian data for all-cause mortality as well as
CVD and CHD specific mortality and synthesized data for synthetic
Austria is shown in figure 1, where both the comparison as well as
plotted gaps (i.e. differences between original and synthesized data)
may be seen. The all-cause, CVD and CHD mortality in synthetic
Austria tracks the trajectories of the variables closely for the entire
period before the TFA regulation. Therefore, the synthetic interna-
tional comparator population provides a sensible counterfactual of
all-cause mortality during 2010–14 in the absence of the TFA
regulation. The year-per-year effect of the TFA regulation on
mortality is the trend difference. Following TFA regulation the
two trends began to diverge slightly. While the mortality in
synthetic international comparator population continued its
moderate downward trend, Austria experienced a small increase.
These empirical patterns do not point to any reductive effect of
the TFA regulation on all-cause mortality.
Sex differences
Data stratified by sex shows similar trends, presented in figures 2 and
3. The gap between Austria and synthetic Austria in the trends of
mortality after introduction of TFA regulations was slightly more
pronounced in women compared to men.
Placebo tests
Figure 4 illustrates results of the 13 placebo tests. The dashed lines
represent the gap between a given country and its synthetic coun-
terpart. The continuous line highlights the gap estimated for Austria
(corresponding to figure 1b). As shown in figure 2, the placebo tests
created gaps of magnitude similar to those estimated for Austria.
Therefore the analysis did not provide significant evidence of a
(negative or positive) effect of the TFA regulation in Austria.
Additionally, figure 4 indicates that all-cause mortality trends
during the period 1995–2009 cannot be reproduced well for some
countries by a weighted average of control countries. Nevertheless
excluding control countries with large pre-treatment errors such as
Estonia did not affect the results. All pseudo-P-values were above the
significance level of 0.05. The series of placebo studies did not
confirm any (pseudo-)significance of the estimated effect.
In unreported analysis, the synthetic control method and the
placebo tests were applied to CVD and CHD mortality for
women, men and both sexes. The results were qualitatively similar
across outcomes and groups, suggesting no discernible effect of the
regulation. Performing a sensitivity analysis involving the exclusion
from the synthetic control of countries that introduced a smoking
ban regulation during the study period did not change these
findings.
Discussion
This analysis evaluated the Austrian policy ban on TFA in the food
supply. The paper is the first to show the effects of an implementa-
tion of such a policy in Austria on a population level. As shown in
table 1, the reduction of the TFA concentration in vegetable oils,
margarine and fine bakery products showed a significant reduction
following the TFA regulation in an analysis of food products. Given
numerous studies that confirm the increased risk of CVD and CHD
when consuming TFA,3,6 and due to an actual reduction occurring,
Figure 1 Comparison of all-cause, CVD and CHD mortality rates per 100 000 people in both sexes with yearly gaps in mortality between
Austria and synthetic international comparator population
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we expected to observe a decrease in our outcome variables, the all-
cause, CVD and CHD mortality. However, even though the
synthetic international comparator population trends follow the
observed Austria trends prior to the policy, providing a very good
approximation, we were unable to demonstrate a decrease in the
mortality trends associated with the TFA policy. Therefore, our
results contradict similar research from other countries as well as
observational studies. For example, a 2016 Danish study reported a
rapid decrease in CVD mortality rates after the implementation of a
similar TFA policy, reporting a decrease in CVD mortality rates of
about 14.2 death per 100 000 people per year relative to the synthetic
control.19 Following a policy on TFA reduction in gastronomic es-
tablishments in New York, it was found that there was a 4.5%
reduction in CVD mortality. The authors further reported that
this reduction could be valued at 3.9 million dollars US annually
per 100 000 people.26
Our results note an overall decrease in all-cause, CVD and CHD
mortality over the investigated period (figures 1–3), however, para-
doxically the mortality trends have declined even further in the
synthetic international comparator population following the TFA
policy implementation, which suggests that the policy implementa-
tion alone has no lowering effect on all-cause, CVD and CHD
mortality. These differences may be driven by a number of alterna-
tive influences on diet and CVD outcomes.
There were differences in the trends of tobacco smoking
prevalence, a known risk factor for all-cause as well as CVD and
CHD mortality. Countries that were used in the calculations for
synthetic Austria show an overall decline in smoking prevalence.25
Unfortunately, this is not the case for Austria, where smoking
prevalence trends do not show a decrease, with the prevalence in
men reported as showing a stable trend and a significant increase in
smoking prevalence in women.27 This could further contribute to
the explanation of our results stratified by sex (figures 2 and 3),
where the gap between Austria and synthetic Austria was more
pronounced in women. The sensitivity analysis and exclusion of
countries was based on the countries that have implemented a
smoking ban in public places. However, there are many other
components to effective tobacco control, including taxation, which
were not considered and might have varied between Austria and
synthetic international comparator population.
A beneficial effect on sub-groups in Austria might not have been
detected in the aggregated data used here. A study using UK and
Dutch data showed that women and non-native population tend to
be among the top consumers of TFAs and so possibly more sensitive
to regulation, while socioeconomic background had no effect.28
Furthermore, a ‘spill-over’ effect of TFA might have played a part
in two different ways: TFA regulation and a growing awareness of
the harms of TFA might have had an international effect reducing
TFA use in the synthetic international comparator populations;
high-TFA foods may continue to be available in Austria through
importation. A study on TFA contents in food products in
Portugal reported that readily available, cheap and highly
consumed pastry products remain an important source of TFA.
Especially worrying were imported pastry products found in ‘low
cost shops’.29 Although such imports may have contributed to our
null finding, this should not be a major influence as the analysis of
the TFA content in Austrian food products has shown a drastic
decrease (table 1).
Figure 2 Comparison of all-cause, CVD and CHD mortality for women rates per 100 000 with yearly gaps in mortality between Austria and
synthetic international comparator population
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Moreover, matching a small set of countries to Austria (which differ
along many dimensions) using synthetic international comparator
population data remains a relatively crude exercise, which may
explain the null finding. Another potential limitation is that the intro-
duction of a specific regulation does not constitute a clear end, but
rather that there is always a ‘wash in’ period in which the industry has
to comply with the regulation followed by the ‘wash out’ period after
the full implementation of the regulation but in which the industry
has still not fully complied. We were not able to clearly differentiate
these periods in the analysis. Additionally, there is a possibility that the
lack of effect is due to the analysis chosen, which might have been
different if multiverse analysis (calculating analyses across a whole set
of alternatively processed data sets corresponding to a large set of
reasonable scenarios) approach was used.30 However, in this paper
Figure 3 Comparison of all-cause, CVD and CHD mortality for men rates per 100 000 with yearly gaps in mortality between Austria and
synthetic international comparator population
Figure 4 Placebo plot: all-cause mortality gaps in Austria and placebo gaps for all 13 synthetic control countries
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we opted for the ‘synthetic control’ method, and have tried various
different analyses (age stratification, with and without inclusion of
smoking regulation or health expenditure and GDP) yet none of
these variations generated a different result.22
In conclusion, whilst the findings of this study are in some ways
counterintuitive, knowing the link between TFA consumption and
an increased risk of CVD and CHD, there are many possible alter-
native explanations that this study was not able to test. Reduction in
TFAs should still be considered an important part of risk reduction
for CVD, CHD and other non-communicable diseases.
This study contributes to the pragmatic research to evaluate
public health interventions, and the use of natural experiment
studies as part of this. However, to enable more in-depth and
meaningful evaluations, countries and the international
community should continue to strengthen monitoring and data
collection, and efforts should be made to further increase the
capacity for high quality evaluations that can influence national
policies and implementation of major risk factor control.
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Key points
 The natural experiment design using the synthetic control
methodology provides a valuable and innovative way of
exploring effects of public health policy.
 We were unable to demonstrate an association between the
implementation of a policy regulation eliminating TFA from
food products in Austria and corresponding changes in all-
cause, CVD or CHD mortality.
 TFA regulation remains an important factor that lowers
mortality of the population, however further public health
policies (such as comprehensive tobacco control) need to be
implemented to achieve a better effect.
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